Skip to content

Assessing the Efficacy and Safety of Collagenase Injection in the Treatment of Cervical Lumbar Intervertebral Disc Herniation: a Exploratory, Single-arm, Open-lable, Multi-center Study

Assessing the Efficacy and Safety of Collagenase Injection in the Treatment of Cervical Lumbar Intervertebral Disc Herniation: a Exploratory, Single-arm, Open-lable, Multi-center Study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063043
Enrollment
Unknown
Registered
2022-08-29
Start date
2022-08-30
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Lumbar Intervertebral Disc Herniation

Interventions

Group 1 :Collagenase injection

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. 18 30 points, full score 100 points; 6. NRS score > 3 points, out of 10 points; 7. The patient fully complies with this agreement in terms of social psychology, spirit, and body, including following the scheduled visits, treatment plans, filling out forms, and being able to complete the content of the comprehension scale.

Exclusion criteria

Exclusion criteria: 1. Concomitant with bony spinal stenosis and nerve entrapment; 2. Cervical disc herniation has degeneration or paralysis of the spinal cord; 3. Severe primary disease or uncontrolled infection, including kidney, heart or liver disease, hematopoietic system, endocrine system disease or pregnancy or breastfeeding 4. Combined with autoimmune diseases affecting the musculoskeletal system (ie lupus, rheumatoid arthritis or ankylosing spondylitis); 5. Has a history of severe drug allergy; 6. Patients with obvious social and psychological diseases and communication barriers; 7. Other patients who are not suitable for participating in the study after being evaluated by the investigator.

Design outcomes

Primary

MeasureTime frame
Odom score;

Countries

China

Contacts

Public ContactDaying Zhang

The First Affiliated Hospital of Nanchang University

zdysino@163.com+86 13507913595

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026